Today: 14 February 2026
Subscribe
Browse Category

ASX:CSL News 20 January 2026 - 10 February 2026

ASX 200 today: Australian shares finish flat as AI fears hit insurers; CSL slides 5%

ASX 200 today: Australian shares finish flat as AI fears hit insurers; CSL slides 5%

The S&P/ASX 200 closed down 2.7 points at 8,867.40, as insurance brokers slumped on AI competition fears. CSL dropped 5% after announcing CEO Paul McKenzie's retirement. Treasury Wine Estates surged over 8% on a U.S. dispute settlement and upgraded earnings forecast. Investors await key earnings from Commonwealth Bank and CSL on Wednesday.
10 February 2026
······
CSL share price in focus after ASX sell-off: what investors watch before Feb 11 results

CSL share price in focus after ASX sell-off: what investors watch before Feb 11 results

CSL Limited shares closed down 0.4% at A$180.50 Friday as the S&P/ASX 200 dropped 2.03% to 8,708.80. CSL will report half-year results and announce its interim dividend on Feb. 11, with the stock set to trade ex-dividend March 10. A filing showed 59,992 CSL conditional rights lapsed this week. The company’s market value stands near A$87 billion, down about a third in the past year.
7 February 2026
···
CSL share price dips in ASX rout — here’s what investors are watching before earnings

CSL share price dips in ASX rout — here’s what investors are watching before earnings

CSL Limited fell 0.41% to A$180.50 as the S&P/ASX 200 dropped 2.03% to 8,709 points on Friday, marking the market’s worst day since November. About 1.23 million CSL shares changed hands ahead of its half-year results due Feb. 11. Healthcare stocks slipped 0.97%, while tech fell 3.7%. CSL reported 59,992 unquoted rights lapsed after processing January leavers, with a cessation date of Feb. 4.
6 February 2026
···
CSL Limited share price rises 2% on ASX — what to know ahead of Feb 11 results

CSL Limited share price rises 2% on ASX — what to know ahead of Feb 11 results

CSL shares rose 2.0% to A$181.70 on Wednesday, outperforming a flat health care sector as the ASX 200 gained 0.8%. Investors await CSL’s half-year results and interim dividend announcement on Feb. 11. The Reserve Bank of Australia raised rates to 3.85% this week, with another hike expected in May. CSL last cut its FY26 forecasts in October, citing weaker U.S. flu vaccination rates.
4 February 2026
·
CSL share price: Two dates now loom after Friday’s lift

CSL share price: Two dates now loom after Friday’s lift

CSL shares closed Friday at A$181.42, up 1.13%, as investors await half-year results and an interim dividend announcement on Feb 11. The RBA meets Feb 2–3, with its decision expected to influence rate expectations and market sentiment. The ASX 200 fell 0.7%, pressured by mining stocks, while healthcare outperformed.
1 February 2026
·
CSL share price rises on ASX as U.S. vaccine policy shifts rattle the sector

CSL share price rises on ASX as U.S. vaccine policy shifts rattle the sector

CSL Ltd shares closed 0.7% higher at A$179.62 Friday, extending Thursday’s gains, with 1.01 million shares traded. The stock’s rise comes as U.S. vaccine policy changes under Health Secretary Robert F. Kennedy Jr. weigh on sentiment for CSL’s Seqirus unit. CSL delayed a Seqirus spinoff and cut its 2026 growth forecast in October, citing falling U.S. flu vaccination rates. Half-year results are due Feb. 11.
23 January 2026
···
CSL share price slips after close as RBC upgrade turns focus to Feb. 11 results

CSL share price slips after close as RBC upgrade turns focus to Feb. 11 results

CSL shares closed down 0.33% at A$176.11 on Wednesday, staying well below last year’s highs. RBC Capital upgraded CSL to “Outperform” and raised its price target to A$230, citing valuation upside despite weak U.S. flu vaccine demand. Investors are focused on CSL’s half-year results and interim dividend due Feb. 11. The S&P/ASX 200 slipped 0.37% amid broader market volatility.
21 January 2026
··
CSL share price edges up after RBC upgrade as investors eye February results

CSL share price edges up after RBC upgrade as investors eye February results

CSL shares rose 0.1% to A$176.70 Tuesday after RBC Capital Markets upgraded the stock, despite the ASX 200 falling 0.66%. The move follows a 36% drop in CSL’s share price over the past year and comes ahead of its Feb. 11 half-year results. RBC cited competition and weak flu vaccine demand as near-term risks. CSL last cut its 2026 revenue and profit growth forecasts in October and delayed its Seqirus spin-off.
20 January 2026
·
1 2 3
Go toTop